TAM
GRCE

Tocqueville Asset Management’s Grace Therapeutics GRCE Stock Holding History

Tocqueville Asset Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1
Closed – – 1320
2014
Q2 		$0 Buy
+1
New +$477 ﹤0.01% 1805

Other funds holding GRCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
CP
Corbenic Partners Bethlehem, Pennsylvania $380M AUM 10.47% 1-Year Est. Return

Tocqueville Asset Management's GRCE Position: Q3 2014 in Review

Tocqueville Asset Management sold out of Grace Therapeutics (GRCE) in Q3 2014, closing a stake of 1 share.

Tocqueville Asset Management first reported a position in GRCE in Q2 2014 and held it in 1 quarter. The position peaked at $0 in Q2 2014. 14 funds tracked by Wall St. Rank hold GRCE as of Q3 2014.

  • Tocqueville Asset Management reported no remaining Grace Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Tocqueville Asset Management sold 1 Grace Therapeutics share in Q3 2014.
  • Tocqueville Asset Management first reported a position in Grace Therapeutics in Q2 2014 and held it in 1 quarter.
  • Tocqueville Asset Management's Grace Therapeutics position peaked at $0 in Q2 2014.
  • 14 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2014.

Based on Tocqueville Asset Management's 13F filing for Q3 2014, filed 30 Oct 2014.